|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US6222020B1
(en)
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
AU598946B2
(en)
|
1987-06-24 |
1990-07-05 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
EP0725145A4
(en)
|
1994-08-23 |
1997-06-11 |
Drug Delivery System Inst Ltd |
PROTEIN MODIFICATION PROCESS
|
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
CA2261989C
(en)
|
1996-07-25 |
2008-09-30 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
EP1012276A2
(en)
|
1997-02-24 |
2000-06-28 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against muc1 tumor-associated antigen
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
JP2003527561A
(ja)
|
1999-01-22 |
2003-09-16 |
スミスクライン・ビーチャム・コーポレイション |
蛋白の部位特異的標識化方法およびそのための使用
|
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
|
AU2001270134B2
(en)
|
2000-06-22 |
2006-06-15 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
|
KR20060032140A
(ko)
|
2003-05-30 |
2006-04-14 |
센토코 인코포레이티드 |
트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
|
|
WO2004106939A2
(en)
|
2003-06-03 |
2004-12-09 |
Paul Scherrer Institut |
Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
EP2033662B1
(en)
|
2004-01-21 |
2012-10-17 |
Novo Nordisk Health Care AG |
Transglutaminase mediated conjugation of peptides
|
|
US20070105770A1
(en)
|
2004-01-21 |
2007-05-10 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
|
EP1729781B1
(en)
|
2004-03-15 |
2012-10-24 |
Karaolis, David K. R. |
A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
|
|
EP1809671B1
(en)
|
2004-11-09 |
2014-07-16 |
University Of Southern California |
CpG/antibody conjugate against cancer
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
ES2567402T3
(es)
|
2006-05-30 |
2016-04-22 |
Genentech, Inc. |
Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
EP3342415B1
(en)
|
2006-08-08 |
2022-01-26 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
|
EP2170353B1
(en)
*
|
2007-05-18 |
2015-06-03 |
AdiuTide Pharmaceuticals GmbH |
Phosphate-modified oligonucleotide analogs with immunostimulatory activity
|
|
NZ599777A
(en)
|
2007-11-07 |
2013-09-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
WO2010002042A1
(ja)
|
2008-07-04 |
2010-01-07 |
国立大学法人 九州大学 |
タンパク質ラベル化用酵素基質
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US8859755B2
(en)
|
2010-03-05 |
2014-10-14 |
Chiralgen, Ltd. |
Method for preparing ribonucleoside phosphorothioate
|
|
US8450293B2
(en)
|
2010-08-10 |
2013-05-28 |
Rutgers, The State University Of New Jersey |
Synthesis and characterization of C8 analogs of c-di-GMP
|
|
US9676871B2
(en)
|
2010-11-05 |
2017-06-13 |
Pfizer Inc. |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US9650427B2
(en)
|
2011-07-22 |
2017-05-16 |
Children's Medical Center Corporation |
Modulators of antiviral signaling pathways and therapeutic uses thereof
|
|
AP2014007595A0
(en)
|
2011-09-30 |
2014-04-30 |
Kineta Inc |
Anti-viral compounds
|
|
AU2012335205A1
(en)
|
2011-11-11 |
2014-05-29 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
EP2596806A1
(en)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Method for prevention of colectomy
|
|
US9764038B2
(en)
|
2011-12-23 |
2017-09-19 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
KR102338833B1
(ko)
|
2012-02-06 |
2021-12-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
|
US20150111246A1
(en)
|
2012-04-24 |
2015-04-23 |
Astrazeneca Pharmaceuticals Lp |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
KR20150030698A
(ko)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
항-cd79b 항체를 포함하는 면역접합체
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
CN104684923B
(zh)
|
2012-07-13 |
2018-09-28 |
株式会社新日本科学 |
手性核酸佐剂
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
KR102165464B1
(ko)
|
2012-07-19 |
2020-10-14 |
레드우드 바이오사이언스 인코포레이티드 |
Cd22에 대해 특이적인 항체 및 이들의 사용 방법
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
PL2931738T3
(pl)
|
2012-12-13 |
2019-07-31 |
Aduro Biotech, Inc. |
Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
|
|
WO2014124433A1
(en)
*
|
2013-02-11 |
2014-08-14 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
WO2014179335A1
(en)
|
2013-04-29 |
2014-11-06 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
CN111437395A
(zh)
|
2013-08-29 |
2020-07-24 |
希望之城 |
细胞穿透缀合物及其使用方法
|
|
AU2014346658A1
(en)
*
|
2013-11-06 |
2016-06-02 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having disulfide groups
|
|
US10556024B2
(en)
|
2013-11-13 |
2020-02-11 |
Whitehead Institute For Biomedical Research |
18F labeling of proteins using sortases
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
癌処置としてのｓｔｉｎｇアゴニストの使用
|
|
JP6865584B2
(ja)
|
2013-12-23 |
2021-04-28 |
コヴァラブ |
化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
TW201623265A
(zh)
|
2014-05-09 |
2016-07-01 |
奇尼塔公司 |
抗病毒化合物、醫藥組合物及其使用方法
|
|
JP2017522046A
(ja)
*
|
2014-06-06 |
2017-08-10 |
ソルスティス バイオロジクス，リミティッド |
生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
US20180134802A1
(en)
|
2016-01-08 |
2018-05-17 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
WO2016079899A1
(ja)
|
2014-11-20 |
2016-05-26 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
|
|
JP6864953B2
(ja)
*
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
|
CA2971246C
(en)
|
2014-12-19 |
2020-07-14 |
F. Hoffmann-La Roche Ag |
Identification of transglutaminase substrates and uses therefor
|
|
WO2016109415A1
(en)
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
|
WO2017011444A1
(en)
|
2015-07-13 |
2017-01-19 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating b cell cancers
|
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
|
|
AU2016297529B2
(en)
|
2015-07-20 |
2021-09-09 |
Zoetis Services Llc |
Liposomal adjuvant compositions
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
CR20180101A
(es)
|
2015-08-13 |
2018-04-12 |
Merck Sharp & Dohme |
Compuestos di-nucleóticos cíclicos como agonistas de sting
|
|
BR112018005322A2
(pt)
|
2015-09-18 |
2018-12-11 |
Arch Oncology, Inc. |
anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
|
|
NZ741324A
(en)
|
2015-09-21 |
2021-09-24 |
Erasmus Univ Medical Center |
Anti-cd47 antibodies and methods of use
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
AU2016365828A1
(en)
*
|
2015-12-08 |
2018-07-05 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
|
|
WO2017143171A1
(en)
|
2016-02-19 |
2017-08-24 |
Genisphere Llc |
Nucleic acid carriers and therapeutic methods of use
|
|
WO2017173427A1
(en)
|
2016-04-01 |
2017-10-05 |
Vycellix Inc |
Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
|
|
SG11201808465UA
(en)
|
2016-04-14 |
2018-10-30 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
|
AR112048A1
(es)
|
2016-05-09 |
2019-09-18 |
Celgene Corp |
Anticuerpos cd47 y métodos de uso de los mismos
|
|
JP6979971B2
(ja)
|
2016-05-09 |
2021-12-15 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
抗ｐｄ−ｌ１抗体
|
|
CN109414500B
(zh)
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
|
CN108350082B
(zh)
|
2016-06-13 |
2021-09-24 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
KR102878970B1
(ko)
|
2016-08-03 |
2025-10-30 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
CN118027200A
(zh)
|
2016-12-09 |
2024-05-14 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
|
MX2019012295A
(es)
*
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
|
CA3103265A1
(en)
|
2018-06-12 |
2019-12-19 |
Angiex, Inc. |
Antibody-oligonucleotide conjugates
|
|
JP7536025B2
(ja)
|
2018-10-17 |
2024-08-19 |
タラック セラピューティクス，インク． |
免疫調節性ポリヌクレオチドコンジュゲートと使用方法
|
|
BR112022017136A2
(pt)
|
2020-02-28 |
2022-10-11 |
Tallac Therapeutics Inc |
Conjugação mediada por transglutaminase
|
|
US20230364255A1
(en)
|
2020-08-18 |
2023-11-16 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|